LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

Masmiquel, Luis; Petrie, John R.; Marso, Steven P.; Bain, Stephen C.; Franek, Edward; Jacob, Stephan; Leiter, Lawrence A.; Haluzik, Martin; Omar, Mohamed; Shestakova, Marina; Van Gaal, Luc; Mann, Johannes F.; Baeres, Florian M. M.; Zinman, Bernard; Poulter, Neil R.; Satman, Ilhan

Date

2016

Author

Masmiquel, Luis

Petrie, John R.

Marso, Steven P.

Bain, Stephen C.

Franek, Edward

Jacob, Stephan

Leiter, Lawrence A.

Haluzik, Martin

Omar, Mohamed

Shestakova, Marina

Van Gaal, Luc

Mann, Johannes F.

Baeres, Florian M. M.

Zinman, Bernard

Poulter, Neil R.

Satman, Ilhan

Metadata

Show full item record

Abstract

Objective: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial.

URI

http://hdl.handle.net/20.500.12627/74999
https://doi.org/10.1097/hjh.0000000000000890

Collections

Makale [92796]